Seyithan TAYSI | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Dr. Seyithan TAYSI | Molecular Biology | Best Researcher Award 

Professor | Gaziantep University | Turkey

Prof. Dr. Seyithan Taysi is a distinguished Professor of Medical Biochemistry at Gaziantep University, widely recognized for his pioneering work on oxidative stress, antioxidant mechanisms, free radicals, and molecular oncology. He earned his Ph.D. in Medical Biochemistry from Atatürk University, where his research on oxidative mechanisms and cellular stress regulation received the Jury’s Special Award for Best Article. Currently, he leads advanced biochemical research and teaching programs, having completed over ninety-five funded projects and holding six patents. His editorial service includes roles on international journal boards such as BioMed Research International and the International Journal of Clinical and Experimental Ophthalmology, where he has reviewed more than four hundred manuscripts. Prof. Taysi’s research focuses on oxidative and nitrosative stress, the Nrf2/Keap1 pathway, and antioxidant-based therapies, integrating biochemical and molecular approaches to improve cancer treatment and radioprotection. He has 162 documents cited by 3,969 documents, with 5,099 citations and an h-index of 39, reflecting his global influence and impact in biomedical research.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Taysi, S., et al. Oxidative stress modulation in cancer therapy. Free Radical Biology & Medicine. Cited by 45 articles.

Taysi, S., et al. Phytotherapeutic agents against radiation-induced cellular damage. Antioxidants (Basel). Cited by 38 articles.

Taysi, S., et al. Nrf2/Keap1 pathway as a therapeutic target in oxidative diseases. Frontiers in Molecular Biosciences. Cited by 62 articles.

Taysi, S., et al. Role of antioxidants in radiotherapy protection. BioMed Research International. Cited by 55 articles.

Taysi, S., et al. Oxidative stress biomarkers in cancer patients. Clinical Biochemistry. Cited by 97 articles.

Shangze Li | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Shangze Li | Molecular Biology | Best Researcher Award 

Assistant to the Dean | Chongqing University | China

Dr. Shangze Li (Ph.D., Associate Professor, Ph.D. Supervisor) is a distinguished researcher in the fields of antiviral innate immune signaling, inflammatory responses, and tumor biology. He is based at the School of Medicine, Chongqing University, where he leads a research group and supervises doctoral students. His work integrates advanced genetic engineering technologies such as gene knockout, knock-in approaches, and disease models to investigate the molecular basis of immune regulation and cancer development. Dr. Li has published extensively in leading international journals including Nature Communications, Cell Death and Differentiation, Cancer Research, Oncogene, and Cancer Letters, with several contributions featured in Nature Index journals. His studies have been widely cited, reflecting both scientific impact and relevance to the global biomedical community. In addition to research, he is actively involved in teaching, mentoring, editorial service, and academic leadership, contributing to the advancement of both education and medical research.

Professional Profile

Scopus

ORCID

Google Scholar

Education 

Dr. Li completed his doctoral degree in Cell Biology at Wuhan University, where he focused on the molecular mechanisms that link immune regulation to tumorigenesis. Prior to his doctoral training, he pursued two undergraduate degrees, one in Bioengineering from the Chengdu University of Technology and another in Business Administration from the University of Electronic Science and Technology of China. This unique combination of scientific and managerial education provided him with both technical expertise and leadership skills. After completing his doctorate, Dr. Li undertook postdoctoral training at the Feinberg School of Medicine, Northwestern University, where he worked on projects exploring molecular oncology, innate immunity, and translational approaches in cancer research. His diverse academic background, spanning engineering, business, molecular biology, and medical research, has prepared him to integrate interdisciplinary knowledge in his career. This foundation continues to guide his role as a scientist, supervisor, and contributor to medical and biological sciences.

Experience 

Dr. Li began his professional research career at the Feinberg School of Medicine, Northwestern University, where he served as a postdoctoral researcher in molecular oncology and immune regulation. Following this period of international training, he returned to China and accepted an appointment at Zhongnan Hospital of Wuhan University and the College of Life Sciences, where he contributed to teaching and research in biomedical sciences. He later joined the School of Medicine at Chongqing University as a faculty member, where he was subsequently promoted to Associate Professor and Ph.D. Supervisor. In this role, he leads a laboratory focused on investigating immune signaling and cancer development. In addition to his research and teaching, Dr. Li has taken on administrative responsibilities, serving as Assistant to the Dean and Deputy Director of Shared Core Facilities for Medical Research. His experience reflects a career that balances leadership, education, and internationally recognized scientific research.

Research Interests 

Dr. Li’s research centers on the molecular mechanisms of innate immune signaling, inflammation, and tumor biology. His work explores how signaling pathways regulate immune homeostasis and contribute to tumor initiation and progression. He employs genetically modified cell lines, CRISPR-based technologies, and animal models to examine the functional roles of key genes in these processes. His studies often focus on ubiquitination and deubiquitination pathways, NF-κB signaling, and the crosstalk between cellular metabolism and cell death. This approach provides critical insights into how molecular dysregulation drives oncogenesis and resistance to therapy. His research also emphasizes translational applications, identifying potential biomarkers and therapeutic strategies that may guide novel approaches in cancer treatment and immune-related diseases. By integrating molecular biology, immunology, and cancer research, Dr. Li contributes to advancing both fundamental scientific knowledge and practical innovations for improving health outcomes.

Awards 

Dr. Li’s research achievements have been recognized through broad citation and publication in top international journals. His scholarly contributions have been acknowledged in Nature Communications, Molecular Cancer, Cancer Research, and other leading journals, with some articles featured as cover stories in Nature Index publications. His body of work has earned substantial recognition in the scientific community, reflected in a strong citation record and consistent invitations to review for leading journals. He has also served as Guest Editor for Vaccines and as a reviewer for the National Natural Science Foundation of China, underscoring his role as a trusted scientific evaluator. Beyond research output, Dr. Li has contributed actively to professional organizations, including serving as a council member of the Chongqing Association of Young Scientists and participating in national academic initiatives. His record demonstrates recognition for both scholarly impact and professional service, positioning him as a strong candidate for scientific honors.

Top Noted Publications 

Dr. Li has authored more than forty peer-reviewed publications, including a substantial number as first or corresponding author. His research has appeared in high-impact journals such as Nature Communications, Molecular Cancer, Oncogene, Cancer Research, and Cancer Letters. Selected publications include Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression in Cells, CLK2 mediates NF-κB regulation in Nature Communications, Crosstalk between metabolism and cell death in tumorigenesis in Molecular Cancer, USP14 promotes colorectal cancer progression in Cell Death & Disease, and MAPK signaling and drug resistance in prostate cancer in Cancer Research. These publications reflect his long-term focus on the molecular basis of immune regulation and cancer biology. His findings have been widely cited and have advanced understanding of tumorigenesis, therapeutic resistance, and immunoregulation. Collectively, his research portfolio highlights his contributions to both fundamental science and translational medicine, strengthening his standing as an influential scholar in the field of biomedical research.

Title: Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression
Journal: Cells
Year: 2024
Cited by: 15+

Title: CLK2 mediates IkappaBalpha-independent NF-κB regulation
Journal: Nature Communications
Year: 2024
Cited by: 30+

Title: Crosstalk between metabolism and cell death in tumorigenesis
Journal:  Molecular Cancer
Year: 2024
Cited by: 40+

Title: USP14 promotes colorectal cancer progression
Journal: Cell Death & Disease
Year: 2023
Cited by: 25+

Title: Activation of MAPK by CXCR7 causes drug resistance
Journal: Cancer Research
Year: 2019
Cited by: 200+

Conclusion

Dr. Shangze Li is a highly suitable candidate for the Best Researcher Award. His outstanding research achievements, strong academic influence, and balanced contributions to teaching, mentorship, and professional service highlight his excellence as a scholar. With continued focus on international collaboration, high-impact publications, and global leadership roles, he is exceptionally well-positioned to be recognized with this award.

Heng Zhang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Heng Zhang | Molecular Biology | Best Researcher Award 

Lecturer | Nankai University | China

Dr. Zhang Heng is a Lecturer in Pharmacology at Nankai University, specializing in investigating the molecular mechanisms underlying malignant tumor progression and developing innovative drug therapies. He earned his B.S., M.S., and Ph.D. in Pharmaceutical Sciences from Nankai University, completing his doctoral studies with high distinction. Since joining the faculty as a lecturer, he has been actively engaged in teaching, mentoring, and advancing cutting-edge cancer research. Dr. Zhang has published multiple high-impact papers in prestigious SCI-indexed journals, including Molecular Cell, Signal Transduction and Targeted Therapy, and Advanced Materials. His scholarly contributions include original research on extrachromosomal DNA, tumor stem cell propagation, and nanomedicine-based immunotherapy. He also holds four patent applications and has received several top academic and innovation awards. Through his research and academic leadership, Dr. Zhang continues to make significant contributions toward improving the understanding of cancer biology and developing novel therapeutic strategies for clinical application.

Professional Profile

ORCID

Education

Dr. Zhang Heng pursued his higher education entirely at Nankai University, a leading institution in China recognized for excellence in pharmaceutical research. He began his academic journey with a Bachelor of Science degree in Pharmaceutical Sciences, where he built a strong foundation in pharmacology, molecular biology, and medicinal chemistry. Continuing at Nankai, he completed his Master of Science degree, focusing on the molecular biology of tumors and early drug discovery methodologies. His master’s research involved extensive laboratory experiments, including molecular cloning, protein analysis, and tumor cell line studies. Dr. Zhang then earned his Ph.D. in Pharmaceutical Sciences, conducting advanced research on the molecular mechanisms driving cancer progression and identifying new targets for therapeutic intervention. His doctoral studies resulted in multiple publications in internationally recognized journals. This academic path, marked by consistent excellence and research productivity, has equipped him with the knowledge and skills essential for his role as an independent researcher and educator.

Experience

Following the completion of his doctoral studies, Dr. Zhang Heng was appointed Lecturer at the College of Pharmacy, Nankai University. In this role, he has been responsible for delivering lectures in pharmacology, supervising undergraduate and graduate students, and leading research initiatives in molecular oncology. He has designed and managed multiple research projects, often collaborating with interdisciplinary teams, and has successfully bridged fundamental science with translational medicine. His experience encompasses conducting high-level molecular biology research, managing laboratory operations, and contributing to scientific publications as both first and corresponding author. He has filed patents for innovative drug delivery systems and tumor immunotherapies, demonstrating the applied impact of his work. Beyond laboratory research, Dr. Zhang has participated in national-level innovation competitions and academic conferences, presenting his findings to peers and experts in the field. His experience reflects a balance of teaching excellence, research innovation, and contribution to the broader scientific community.

Research Interest

Dr. Zhang Heng’s research interests lie at the intersection of cancer biology, molecular pharmacology, and drug innovation. He investigates the fundamental mechanisms that drive the malignant progression of tumors, including the role of extrachromosomal DNA, R-loop dynamics, and vasculogenic mimicry. His work also explores how specific proteins and epigenetic factors regulate tumor growth, immune evasion, and stem cell maintenance. In addition to basic research, Dr. Zhang focuses on developing new therapeutic strategies, such as tumor-targeted nanomedicines, biomimetic exosomes, and in situ tumor vaccines. He aims to integrate these novel approaches into translational medicine frameworks, ultimately leading to more effective, personalized cancer treatments. His interdisciplinary methodology combines molecular biology, pharmacology, nanotechnology, and immunotherapy, with the overarching goal of creating clinically applicable solutions for some of the most aggressive and treatment-resistant cancers. This research focus reflects both scientific curiosity and a commitment to advancing healthcare outcomes.

Award

Dr. Zhang Heng has been recognized for his outstanding research achievements, innovative contributions, and academic excellence through multiple prestigious awards. He received the Second Prize of the Tianjin Science and Technology Progress Award, which acknowledges impactful scientific advancements with practical applications. His innovative work in drug development and cancer therapy earned him the Gold Award at the China International “Internet Plus” Innovation and Entrepreneurship Competition. In recognition of his leadership, scientific merit, and contributions to society, he was awarded the Tianjin May Fourth Youth Medal. While a student, Dr. Zhang received the Zhou Enlai Scholarship, the highest honor granted by Nankai University, and was named Nankai University Student of the Year. These distinctions highlight not only his research excellence but also his dedication to innovation, community engagement, and the advancement of pharmacological sciences on both a national and international level.

Top Noted Publication

Dr. Zhang Heng has authored a series of impactful publications in high-ranking scientific journals, contributing significantly to the fields of molecular oncology and drug development. His research outputs span mechanistic cancer biology studies, novel therapeutic approaches, and the application of nanotechnology in tumor immunotherapy. These publications have been cited in multiple peer-reviewed articles, demonstrating their influence within the global scientific community. His work continues to inform and inspire ongoing research in cancer treatment innovation.

Publications list (single-line prompt):

Title: Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1–Lig3–PARylation complex
Journal: Molecular Cell
Year: 2025

Title: MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells
Journal: Signal Transduction and Targeted Therapy
Year: 2021

Title: Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
Journal: Advanced Materials
Year: 2022

Title: Magnetic sculpture-like tumor cell vaccines enable targeted in situ immune activation and potent antitumor effects
Journal: Theranostics
Year: 2025

Title: Vitamin D binding protein (VDBP) hijacks Twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma
Journal: Theranostics
Year: 2024

Conclusion

Dr. Zhang Heng is a highly suitable candidate for the Research for Best Researcher Award. His combination of scientific excellence, innovation, and societal impact aligns well with the award’s criteria. With continued growth in global collaboration and academic leadership, he has the potential to become a leading figure in pharmacology and cancer research worldwide.